An intriguing side effect of Grb2 phosphorylation as a potential negative regulator is that tyrosine kinase inhibitors, such as those widely used as cancer therapeutics in EGFR-driven cancers (64), could also inhibit this negative regulatory mechanism—conceivably interfering with their desired effects. Here, GRB2 is linked to cancer.